AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Intranasal vaccination with murine parainfluenza virus type I (Sendai virus) was safe and immunogenic in healthy human adults.
"Human parainfluenza virus-type 1 (hPIV-1) is the most common cause of pediatric laryngotracheobronchitis (croup) and results in close to 30,000 U.S. hospitalizations each year. No effective vaccine is available. We examined murine PIV-1 (Sendai virus, SeV) as a live, xenotropic vaccine for the closely related human PIV-1 in a phase 1, dose escalation study in healthy adults," scientists in the United States report.
"Intranasal Sendai virus was uniformly well-tolerated and showed evidence of immunogenicity in three of nine vaccinees despite pre-existing, cross-reactive immunity presumably induced by previous exposure to human PIV-1," stated Karen S. Slobod and collaborators at St. Jude Children's Research Hospital and the University of Tennessee in Memphis. "Results encourage future trials to evaluate the efficacy of Sendai virus in preventing human PIV-1 ...
Source: HighBeam Research, Sendai virus vaccine is safe and immunogenic in healthy adults.